Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07082309

The Effect of Ketone Monoesters on Skeletal Muscle Protein Synthesis and Whole-body Protein Metabolism.

The ketone β-hydroxybutyrate (BHB) is endogenously produced during periods of low glucose availability, serving as an alternative metabolic fuel. Beyond its role as an energy substrate, BHB acts as a pleiotropic signalling molecule, modulating various physiological processes across multiple tissues. BHB can also be ingested orally as a ketone monoester, transiently elevating plasma concentrations of BHB to a level similar to those seen following several days of fasting, thereby obviating the need for dietary manipulation. The influence of BHB on human skeletal muscle protein metabolism remains poorly understood, although emerging evidence suggests that BHB may play a role in regulating muscle protein turnover. As such, BHB supplementation may support skeletal muscle remodelling and offer therapeutic benefits, and investigating this is of considerable interest. This study will investigate the ability of oral BHB ingestion - co-ingested with protein - to stimulate skeletal muscle anabolism in young healthy adults. A dual amino acid stable isotope tracer approach will be utilised to determine postprandial (i.e., fed state) muscle protein synthesis (MPS) rates and whole-body amino acid kinetics, given BHBs systemic effects. This research will advance our understanding of the fundamental biology of exogenous ketosis and provide insight into the potential of BHB supplementation as a novel nutritional strategy to optimise muscle mass and quality.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Health and Life Sciences

Exeter, Devon, EX1 2LU, United Kingdom

Location status: Recruiting

Location contact

Alistair Monteyne, PhD

CONTACT

[email protected]

+44 (0)1392 72 4774

Alistair Monteyne, PhD

PRINCIPAL_INVESTIGATOR

About this study

The ketone body β-hydroxybutyrate (BHB) is produced endogenously during periods of low glucose availability (e.g., fasting or starvation) and provides an alternative metabolic fuel. BHB also acts as a metabolic signalling molecule, modulating physiological processes across multiple tissues, including skeletal muscle. However, the impact of exogenous ketosis on muscle protein turnover, which regulates muscle mass and modulates physical function, remains largely unexplored. As such, understanding how BHB affects skeletal muscle protein turnover is fundamentally important. The ingestion of 0.5g/kg body mass BHB appreciably increases plasma BHB concentrations for several hours, to ~3-5 mM; equivalent to several days of fasting. This offers a model to exogenously elevate plasma BHB concentrations and investigate how BHB interacts with feeding to affect postprandial protein metabolism, the period primarily responsible for driving changes in muscle quality and quantity.

An early study demonstrated that the infusion of BHB stimulates muscle protein synthesis rates (MPS), whilst only a single recent study has investigated the effect of oral BHB ingestion (exogenous ketosis) on MPS. Prior work demonstrated that the ingestion of an oral ketone monoester stimulated MPS, and it did so to a similar extent as 10 g whey protein or co-ingestion of the two, in healthy young males. While this study provides useful insights, several unanswered questions/objectives that justify the need for further investigation remain:

  • To determine how BHB ingestion influences myofibrillar protein synthesis, plasma amino acid concentrations, and amino acid kinetics following the co-ingestion of a physiologically relevant meal-like protein dose.
  • To examine how BHB ingestion affects plasma amino acid concentrations and kinetics following protein co-ingestion, addressing prior research limitations where differences in carbohydrate intake and postprandial insulin levels confounded the independent effects of ketones.
  • To assess the impact of BHB ingestion on whole-body protein metabolism following protein co-ingestion, as previous studies have not examined its potential influence on protein breakdown, amino acid kinetics, and net protein balance.
  • To investigate whether BHB ingestion influences mitochondrial muscle protein synthesis following protein co-ingestion, given its established effects on mitochondrial metabolism, yet unexamined role in mitochondrial protein turnover.

The aim, therefore, is to establish the effect of BHB and protein co-ingestion on myofibrillar protein synthesis rates, mitochondrial protein synthesis rates, and whole-body protein turnover. We will address this question by utilising a meal-like bolus of protein (0.3 g/kg whey protein), with and without 0.5g/kg body mass BHB (matching the test drinks caloric content via the addition of fat to minimally stimulate insulin secretion), whilst applying a dual-stable isotope tracer approach.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • BMI 18-30

Exclusion criteria

  • Body mass index (BMI) < 18.5 or > 30 kg/m2
  • Age < 18 or > 40
  • Regularly smokes
  • Type 2 diabetes
  • Cardiovascular disease, metabolic disease and hypertension (≥ 140/90 mmHg)
  • Gastrointestinal disorders
  • Use medicines that may impact protein metabolism or that are anti-inflammatory (determined at the screening)
  • Pregnancy

Treatment and study plan

Ketone Monoester (KE) and whey protein beverage

Dietary Supplement

Ketone monoester ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate) and whey protein (0.3 g/kg)

Control

Dietary Supplement

Placebo with bitter agent (Bitrex), to flavour match to ketone condition, whey protein (0.3 g/kg), and milk fat (to match the caloric content of the ketone condition).

Primary outcomes

  1. Skeletal muscle protein synthesis rates (FSR)

    Time frame: 5 hours (2 hours postabsorptive, 3 hours postprandial)

    Skeletal muscle protein synthesis rates

Secondary outcomes

  1. Plasma amino acid concentrations

    Time frame: 5 hours

    Plasma amino acid concentrations

  2. Whole-body phenylalanine kinetics assessed by stable isotope tracer methodology, including rate of appearance (Ra), rate of disappearance (Rd), hydroxylation rate, and net balance.

    Time frame: 5 hours (2 hours postabsorptive, 3 hours postprandial)

    Whole-body kinetics of phenylalanine will be quantified using a primed continuous intravenous infusion of stable isotope-labelled phenylalanine and tyrosine tracers (e.g., L-[ring-²H₅]-phenylalanine and L-[³-¹³C]-tyrosine). Arterialised-venous blood samples will be collected at steady state to determine tracer enrichment in plasma.

    The following parameters will be calculated:

    Rate of appearance (Ra) of phenylalanine (μmol/kg/min), rate of disappearance (Rd) of phenylalanine (μmol/kg/min), hydroxylation rate of phenylalanine to tyrosine (μmol/kg/min) (derived from the appearance of labelled tyrosine from labelled phenylalanine), and net balance of phenylalanine (μmol/kg/min): calculated as the difference between Ra and Rd to assess overall protein balance.

  3. Serum insulin concentrations

    Time frame: 5 hours

    Serum insulin concentrations

  4. Plasma beta hydroxybutyrate concentrations

    Time frame: 5 hours

    Plasma beta hydroxybutyrate concentrations

Study contacts

Contact information is provided by the study sponsor or research team.

Alistair Monteyne, PhD

CONTACT

[email protected]

+44 (0)1392 72 4774

Sponsors and collaborators

Lead sponsor

University of Exeter

Other

Registry information

Acronym: WAKM

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Jul 24, 2025
Registry last updated
Jul 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.